News Summary: Actavis plans Warner Chilcott deal

Published



THE OFFER: Actavis Inc. said Monday that it has agreed to buy fellow drugmaker Warner Chilcott PLC in an all-stock deal valued at about $8.5 billion.

THE PARTICULARS: Warner Chilcott shareholders will receive 0.16 shares of the new company for each share they own. This equals $20.08 per share, and they would then own a 23 percent stake in the new company.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.